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and Ilka U. Heinemanna
a
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ABSTRACT

ARTICLE HISTORY

The de-regulation of microRNAs (miRNAs) is associated with multiple human diseases, yet cellular
mechanisms governing miRNA abundance remain largely elusive. Human miR-122 is required for
Hepatitis C proliferation, and low miR-122 abundance is associated with hepatic cancer. The adenylyltransferase Gld2 catalyses the post-transcriptional addition of a single adenine residue (A + 1) to the 3ʹend of miR-122, enhancing its stability. Gld2 activity is inhibited by binding to the Hepatitis C virus core
protein during HepC infection, but no other mechanisms of Gld2 regulation are known. We found that
Gld2 activity is regulated by site-specific phosphorylation in its disordered N-terminal domain. We
identified two phosphorylation sites (S62, S110) where phosphomimetic substitutions increased Gld2
activity and one site (S116) that markedly reduced activity. Using mass spectrometry, we confirmed that
HEK 293 cells readily phosphorylate the N-terminus of Gld2. We identified protein kinase A (PKA) and
protein kinase B (Akt1) as the kinases that site-specifically phosphorylate Gld2 at S116, abolishing Gld2mediated nucleotide addition. The data demonstrate a novel phosphorylation-dependent mechanism to
regulate Gld2 activity, revealing tumour suppressor miRNAs as a previously unknown target of Akt1dependent signalling.
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Introduction
MicroRNAs (miRNAs) are critical regulators of gene expression
that are essential to human life, normal cellular function, and
development. De-regulation of miRNAs is, perhaps not surprisingly, associated with a number of human diseases[1]. MiRNAs
regulate the expression of many genes, including oncogenes, by
complementary base pairing with the 3ʹ-untranslated regions
(UTRs) of mRNAs, which normally inhibits protein synthesis[1].
MiRNAs themselves are post-transcriptionally regulated by the
addition of single or multiple adenine (A) or uridine (U) residues
to their 3ʹ-ends. This untemplated RNA editing is now recognized
as an important mechanism regulating cellular miRNA homeostasis [2,3]. The addition of a single A to the 3ʹ-end on certain
miRNAs leads to increased stability [4]. Conversely, the activity of
mature miRNAs is reduced by the addition of a single 3ʹ-U residue
[5,6]. The addition of multiple U residues to precursor miRNAs
(pre-miRNAs) triggers subsequent degradation by the U-specific
exonuclease Dis3L2 (Dis3-like exonuclease 2) [3]. Although uridylation is commonly associated with silencing and degradation
of RNAs, monouridylation of Group II pre-miRNAs lacking
a critical 3ʹ-end overhang nucleotide is required for miRNA
maturation and processing by Dicer [7]. Cellular mechanisms
that regulate miRNAs through 3ʹ-terminal nucleotide additions
are of fundamental relevance to the molecular basis of diseases
characterized by de-regulated miRNA metabolism [3,8].
A diverse family of terminal nucleotidyltransferases
(TENTs) catalyses 3ʹ-A and U additions to RNAs in human
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cells. The nucleotidyltransferase Gld2 (germline development
2, TENT2) was first identified as a regulator of meiosis in
Caenorhabditis elegans [9] and was later shown to extend the
poly(A) tails of mRNAs (Figure 1a), leading to enhanced
mRNA stability and increased abundance of the encoded
protein [10]. In humans, Gld2 stabilizes miR-122 in the liver
and fibroblasts through mono-adenylation [4,11] and mRNAs
via poly-adenylation [12] (Figure 1a).
Gld2 is thought to be part of a larger protein complex
involved in RNA modification and germ cell formation [13].
Although some reports [7] suggested that Gld2 may function as
a uridylyltransferase, we recently characterized human Gld2 as
a bona fide adenylyltransferase [14]. Our data confirmed a basal
activity of Gld2 with U, but the 80-fold higher catalytic efficiency
for ATP makes the enzyme strongly selective for A additions
[14]. Gld2 encodes a nucleotidyltransferase domain and a poly(A) polymerase-associated domain that are required for catalytic
activity as well as a disordered N-terminal domain of unknown
function [10] (Figure 1b), yet lacks identifiable RNA binding
motifs. The crystal structure of a truncated C. elegans Gld2 in
complex with the interacting protein Gld3 shows that the two
essential Gld2 catalytic domains share the same fold as other
nucleotidyltransferases [15].
Cellular mechanisms that regulate miRNAs through 3ʹ-end
nucleotide additions are of fundamental relevance to the
molecular basis of diseases characterized by de-regulated
miRNA metabolism [3,8]. Gld2 and its substrate miR-122
play a role in Hepatitis C virus (HCV) infection and in
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Figure 1. Pathways regulated by Gld2 and domain architecture. (a) Known functions of Gld2. Gld2 stabilizes mature miRNA and mRNA through monoadenylation or polyadenylation of the 3ʹ-end. Mononucleotide addition of Group II pre-miRNAs on the 3ʹ-end by Gld2 allows recognition by Dicer to be processed to mature
miRNAs. This is followed by strand selection by Argonaute (AGO) and incorporation into the RNA-induced silencing complex (RISC). The different pathways are
represented by solid or dashed lines. (b) Schematic of Gld2 showing the nucleotidyltransferase domain (NTR) and poly(A) polymerase-like domain (PAP).

hepatic cancer [16]. MiR-122 is one of the most abundant
miRNAs in the liver, with an essential role in maintaining
liver homeostasis and differentiation [16]. During HCV infection, miR-122 binds to two sites in the viral 5ʹ-UTR of the
Hepatitis C viral RNA and is required for HCV infection
[16,17]. The miR-122 interaction with the 5ʹ-UTR enhances
viral replication by increasing the formation of ribosome
complexes to increase viral protein production. The binding
of miR-122 to protein argonaute-2 (Ago2) in the RNAinduced silencing complex (RISC) also protects viral RNA
from exonucleases [16]. Interestingly, the HCV core protein
was shown to bind to Gld2 in the cytoplasm and inhibit its
nucleotide addition activity. The subsequent reduction in
miR-122 abundance allows HCV to maintain low levels of
viral protein production to facilitate continuous viral replication and infection of host cells [18]. Consequently, inhibition
of Gld2 by the HCV core protein decreases miR-122 stability
and abundance. Low miR-122 levels, in turn, are associated
with hepatic cancer, linking HCV infection to the development of hepatocellular carcinoma (HCC) [18,19]. Hepatitis
B virus X-protein (HBx) was also shown to reduce Gld2
protein levels and cause an increase in cationic amino acid

transporter 1 (CAT-1), a target of miR-122 [20–22]. CAT-1 is
involved in the tumorigenesis of the Hepatitis B virus (HBV)
[20]. Miravirsen, an anti-miR-122 oligonucleotide, is in Phase
II trials to treat Hepatitis C and has been shown to decrease
levels of miR-122 for a prolonged period of time, resulting in
decreased HCV RNA levels in patients [23–25]. As high levels
of miR-122 have been observed in colorectal liver metastasis,
Miravirsen has been suggested as a potential anti-cancer drug
as well [26].
While it is clear that Gld2 plays a role in promoting miRNA
stability [3,14,16], cellular mechanisms that regulate Gld2 activity were previously unknown. In HCC cells, miR-122 is destabilized despite no observed changes in Gld2 protein levels [18,19].
These data suggest the existence of a clinically relevant mechanism that regulates Gld2 activity via post-translational modification. We demonstrate that Gld2 activity is indeed regulated by
phosphorylation. We found that Gld2 is phosphorylated at specific serine residues in the disordered N-terminal domain
in vivo, which dramatically impact catalytic activity and substrate
specificity. We found protein kinases A (PKA) and B (Akt1) sitespecifically phosphorylate Gld2 at S116, which abolishes 3ʹnucleotide addition activity. The data reveal tumour suppressor
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miRNAs as a previously unrecognized target of oncogenic protein kinases.

Results
Gld2 plays an important role in miRNA stability, but the
regulation of Gld2 activity or substrate specificity is unknown.
Studies in other nucleotide polymerases [27,28] found that
phosphorylation of serine and threonine residues can increase
activity or processivity. For example, serine phosphorylation
in the disordered C-terminal domain of RNA polymerase II is
required for transcription initiation and elongation [27].
Phosphorylation of the terminal uridylyltransferase Tut1 at
S6 is required for Tut1 nuclear retention and regulation of
specific mRNAs [28]. Multiple independent proteome-level
mass spectrometry studies of human cells revealed phosphorylated residues in Gld2 [29–31], including five conserved
serine residues (S62, S69, S95, S110, S116) in the disordered
N-terminal domain (Figure 2). Despite these observations, the
putative Gld2 kinase(s) and the impact of phosphorylation on
Gld2 activity was unknown.

Phosphorylation of the Gld2 N-terminal domain in HEK
293 cells
Although the above studies suggest the existence of a Gld2 kinase
in human cells, we analysed Gld2 following incubation with
HEK 293 cell lysates to confirm phosphorylation activity
towards Gld2. The HEK 293 cells were stimulated with epidermal growth factor (EGF) to activate cellular kinases. Purified
Gld2 (Figure S1) was incubated with cell extracts from HEK 293
cells after EGF stimulation of signalling pathways. The phosphorylation status of Gld2 was subsequently analysed by mass
spectrometry, and we unambiguously identified phosphorylation at S62 in the sample incubated with EGF-stimulated cell
lysate (Figure 3b). We did not identify pS62 in unstimulated cells
or in recombinantly produced Gld2. As Gld2 has been previously shown to be involved in miRNA metabolism [4,7], this
indicates the existence of physiologically relevant signalling
pathways connecting EGF-stimulated protein kinases to

miRNA metabolism via phosphorylation-dependent regulation
of Gld2. EGF activates many cellular pathways involved in
regulating growth, proliferation, differentiation, and survival.
EGF binds to receptor tyrosine kinases, leading to their activation. This in turn activates cascades of cellular kinases. Within 10
min of EGF stimulation, mammalian cells display 100s of new
phosphorylation events [32]. Data from this study also indicate
that following EGF stimulation 30 tyrosine and more than 100
serine/threonine kinases are activated by phosphorylation,
which may be responsible for S62 phosphorylation. Any of
these serine/threonine kinases are potential candidates for catalysing S62 phosphorylation.

Gld2 N-terminal domain phosphomimetic variants
regulate catalytic activity
To rapidly assess the effects of phosphorylation at positions in
the Gld2 N-terminal domain, human Gld2 variants were
produced in Escherichia coli with respective serine phosphorylation sites mutated to the phosphomimetic glutamic acid
[33]. Wild type and phosphomimetic Gld2 variants were
produced and purified to homogeneity (Figure S1). Kinetic
parameters for specific activity and binding affinity were
determined for wild-type Gld2 and phosphomimetic variants
with glutamate substitutions at the phosphorylation sites S62,
S69, S95, S110, and S116.
Nucleotide addition activity was measured by incubating
each enzyme variant with an RNA substrate and [α-32P]-ATP
(Figure 4, and S2A, S2B). Enzymatic and binding assays were
conducted with RNA substrates miR-122 and a mRNA poly(A)
tail mimic of 15 adenine residues (15A). MiR-122 and 15A RNA
were used based on previous studies demonstrating their competence as Gld2 substrates [4,14].
Depending on the residue location, phosphomimetic substitutions had distinct effects on enzyme activity (Table 1, Figure 4).
S62E markedly increased activity with both RNAs compared to
wild-type Gld2, indicating an overall activating effect. In contrast,
an S116E mutation severely decreased Gld2 activity with miR-122
and 15A RNA. Interestingly, S110E increased activity for miR-122
but decreased activity for 15A RNA. Gld2 S69E showed no

Figure 2. Multiple sequence alignment of mammalian Gld2 sequences. Sequences were downloaded from NCBI and the alignment and editing were performed
with Muscle [68], MultiSeq from VMD 1.8.7 [69], and Wasabi [70]. Numbers above the alignment indicate the position in H. sapiens Gld2.
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Figure 3. Gld2 is phosphorylated at S62 when incubated with EGF-stimulated HEK 293 cell extract. Mass spectra of Gld2 after incubation with cell extracts
from EGF stimulated HEK 293 cells showing (a) unphosphorylated S62 and (b) phosphorylation at S62 (bolded and underlined). The intensity for y and b-ions
resulting from fragmentation of the peptide containing S62 is shown; these intensities are overlaid on the retention time position of the full peptide mass. M/z values
for each y and b ion are shown. Gld2 was isolated using a GST Spintrap column before mass spectrometry. Trypsin was used to generate the Gld2 peptides and the
ions from the peptides are shown in the mass spectra. A full scanning was performed to obtain all possible modifications and was followed by parallel reaction
monitoring (PRM) to verify the modification at S62.

significant changes in activity for either RNA while S95E was
1.6-fold more active with 15A RNA.
Based on a comparison of the specific activities (Figure 4,
Table 1), only S62E and S116E displayed statistically significant changes in activity with both RNA substrates. S62E
enhanced the nucleotide addition activity by ~5-fold. S116E
exhibited the opposite effect, decreasing Gld2 activity by 111fold with miR-122 and 16-fold with 15A RNA. As the S62E
and S116E mutants displayed opposite effects on Gld2 activity, a double mutant (S62E, S116E) was generated to investigate cumulative effects. Interestingly, the inhibitory effect of
the S116E mutation overpowered the activating effect of the
S62E mutation and decreased the activity of Gld2 74-fold with
miR-122 and 5-fold with 15A RNA compared to the wild type
enzyme. The double mutant counteracted the silencing effect
of S116E alone by 3.1-fold with 15A RNA and 1.5-fold with
miR-122.
The ability of the mutants to alter the nucleotide addition
activity varied between RNA substrates. The molecular basis for
the higher specific activity of Gld2 with miR-122 compared to
15A RNA remains to be elucidated to discern whether Gld2

recognizes a specific RNA sequence and/or discriminates substrates based on the RNA length.
Gld2 phosphomimetic substitutions impact RNA substrate
affinity
As changes in catalytic activity were RNA-dependent, the
RNA binding affinities of all Gld2 phosphomimetic variants
were quantified using fluorescence anisotropy (Figures S2C,
S2D). The binding affinities (KD) for all enzyme variants were
in the nanomolar range (Figure 4, Table 1). Changes in RNA
binding affinity were substrate dependent. The binding affinity to miR-122 was unchanged for most mutants, except for
S62E, which showed a 5.5-fold increase in RNA binding
compared to wild-type Gld2 with miR-122. The same mutant
showed no change in binding to a 15A substrate. For the 15A
RNA, two mutants (S69E and S95E) showed a decrease in
affinity, while all other mutants showed no change. With
a 6.6-fold reduced KD compared to wild type, Gld2 S95E
showed the most dramatic impact on 15A RNA binding;
S69E was 3.3-fold decreased in binding affinity to 15A.
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Figure 4. Phosphomimetic Gld2 variants modulate catalytic activity and RNA binding. (a) Activity assay gels of wild type and mutant Gld2. Wild type (WT) Gld2
and glutamic acid mutants were incubated with [α-32P]-ATP and miR-122 (22 nts) or 15A RNA (15 nts) at 37°C with samples taken every 2 min for 8 min. Reactions
were repeated in triplicate (R1-3) and analysed via gel electrophoresis and phosphorimaging. A no enzyme control was performed for each RNA substrate in triplicate
and the average of the no enzyme triplicates for each RNA was calculated for the 0-min time point. Reaction products were quantified by exposing a Whatman filter
strip dotted with different known concentrations of [α-32P]-ATP to the same phosphorscreen as the gel. R, replicate. (b) and (c) Bar graphs showing the fold change
in specific activity (SA) at 1 µM ATP and binding affinity (KD) between wild-type Gld2 and Gld2 glutamic acid mutants with (b) miR-122 (22nt) or (c) oligo(A) tail
mimic 15A RNA (15nt). Each Gld2 variant was incubated with 1 µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate. Samples were taken every 2 min and
stopped with the addition of 2x RNA loading dye. Reactions were analysed via electrophoretic separation and subsequent phosphorimaging. Specific activity is the
activity of an enzyme per milligram of purified enzyme and was calculated from the linear slope of the curve. Fluorescence anisotropy was used to determine the KD.
Each Gld2 enzyme was incubated with a RNA substrate fluorescently labelled on the 5ʹ-end with 6-FAM and incubated at room temperature for 20 min. Fluorescence
polarization was measured at Ex. 492 nm and Em. 535/20 nm and the KD was calculated using SigmaPlot. Error bars represent one standard error calculated from
triplicate reactions. Significant changes calculated using a two-tailed t-test are indicted by asterisks. p ≤ 0.05 (*); p ≤ 0.01 (**); p ≤ 0.001 (***). Fold changes were
calculated using data from Table 1 and Figure S2.

Table 1. Activity and RNA-binding of wild type (WT) and phosphomimetic Gld2
variants.
miR-122
WT
S62E
S69E
S95E
S110E
S116E
S62E, S116E
S116A

SA (µmol/min/mg)
3452 ± 182
14,186 ± 774
4670 ± 272
2191 ± 78
7340 ± 433
31 ± 5
47 ± 2
150 ± 0.05

15A RNA
KD (nM)
15 ± 3
2.7 ± 0.8
30 ± 9
22 ± 6
18 ± 5
19 ± 5
12 ± 3
35 ± 7

SA (µmol/min/mg)
448 ± 10
2919 ± 239
555 ± 22
698 ± 30
171 ± 7
28 ± 0.05
89 ± 6
38 ± 16

KD (nM)
1.7 ± 0.3
2.3 ± 0.3
5.8 ± 1.1
11 ± 2
2.9 ± 0.6
3.8 ± 0.8
3.4 ± 0.6
7.4 ± 1.8

Standard error is reported; specific activities (SA) at 1 µM ATP.

Overall, our phosphomimetic analysis suggests that each
phosphorylation site has a distinct role in regulating Gld2
activity or substrate selectivity. We found that S62E increases
activity with either no change (15A) or with increased binding
affinity (miR-122), which may favour miRNA over mRNA
stabilization. S69E and S95E caused no significant change in

activity, but decreased affinity towards 15A RNA, indicating
a reduced preference for mRNA adenylation. S110E appears
to have an insignificant impact on activity and binding on the
tested substrates. Finally, S116E and the S62E/S116E double
mutant markedly reduced activity without significantly
impacting RNA binding. The data indicate that Gld2 S116E
and the double mutant are able to bind to the RNA target, but
perhaps not in a catalytically competent conformation.
PKA and Akt1 site-specifically phosphorylate Gld2 at
S116
As the phosphomimetic mutants displayed significant changes
in activity and RNA substrate binding compared to wild-type
Gld2, we next identified kinases that phosphorylate the Gld2
N-terminus. PhosphoMotif Finder [34] and GPS 3.0 [35] were
used to generate a list of potential kinases (Table S2). Using the
kinase assay detailed in Materials and Methods, wild-type Gld2
was incubated with recombinant and active human kinases

RNA BIOLOGY

(CK2α, CK2 holoenzyme, CDK5, PKA, and Akt1) predicted to
have a recognition motif in Gld2 (Figure 5a). The kinase Abl,
which was not identified as a potential Gld2 kinase, was used as
a negative control. We used our recently developed approach
[36] combining genetic code expansion with in vivo enzymatic
phosphorylation to prepare fully activated and purified recombinant Akt1 with programmed phosphorylation at both activating sites (ppAkt1T308,S473). This method involves protein
production in an E. coli strain that co-expresses the kinase
PDK1 to phosphorylate Akt1 at T308. The strain also genetically
encodes phosphoserine (pSer) at UAG codons. The serine codon
at position 473 was replaced with a UAG codon to direct pSer
incorporation in Akt1.
Following incubation of Gld2 and [γ-32P]-ATP with each
kinase in separate reactions, the radio-labelled phosphorylated
Gld2 (pGld2) product was only observed when Gld2 was incubated with PKA or ppAkt1T308,S473 (Figure S3, Figure 5a).
Quantification of the Akt1-dependent reaction showed a rapid
increase in phosphorylated Gld2 over a 15-min time course
(Figure 5b). Independent pGld2 preparations resulting from
incubation with PKA or ppAkt1T308,S473 were analysed by mass
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spectrometry to determine the site(s) of phosphorylation. Both
un-phosphorylated Gld2 and Gld2 incubated with CK2α, which
was inactive in phosphorylating Gld2, were also analysed by
mass spectrometry as controls (Figure 5c). S116 was unambiguously identified as the site of specific phosphorylation by Akt1
and PKA. Phosphorylation at S116 was not observed in unphosphorylated Gld2 or in the preparation incubated with
CK2α. Next, S116 was mutated to an alanine residue (Figure
S1) to determine if S116 represents the sole Akt1 and PKA
phosphorylation site on Gld2. The kinase assay was repeated
with Gld2 S116A incubated with PKA or ppAkt1T308,S473 (Figure
5a). For both kinases, no phosphorylated Gld2 S116A product
was observed, confirming that PKA and Akt1 phosphorylate
Gld2 specifically and exclusively at S116.
Phosphorylation of Gld2 at S116 abolishes nucleotide
addition activity
The phosphomimetic mutant (S116E) was not competent in
nucleotide addition, yet the variant retained RNA binding affinity
(Figure 4, Table 1). As Akt1 and PKA both phosphorylate S116,

Figure 5. Akt1 and PKA phosphorylate Gld2 at S116. (a) Gld2 or Gld2 S116A were incubated with [γ-32P]-ATP and the indicated kinases. Formation of
phosphorylated Gld2 (75 kDa) was monitored by electrophoretic separation and subsequent phosphorimaging. R, replicate. (b) Quantification of phosphorylated
product formation from a kinase reaction over 15 min. Doubly phosphorylated Akt1 displays a low level of autophosphorylation, which we measured in the absence
of a substrate peptide. (c) Mass spectra of unphosphorylated Gld2 or Gld2 phosphorylated by CK2α, ppAkt1T308,S473 (ppAkt1), or PKA. Unphosphorylated peptide is
indicated by the light pink peak and the phosphorylated peptide by the dark pink peak. Position 116 is bolded and underlined. (d) Bar graphs showing the fold
change in specific activity (SA) at 1 µM ATP between treated WT (tWT) and Gld2 phosphorylated by PKA with miR-122 (22nt) or oligo(A) tail mimic 15A RNA (15nt).
The inset shows the fold change in activity of Gld2 phosphorylated by PKA compared to tWT. Error bars show one standard error calculated from triplicate reactions.
Significant changes calculated using a two-tailed t-test are indicted by asterisks. p ≤ 0.001 (***).
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we produced pGld2S116 following incubation with PKA as noted
above to investigate the nucleotide addition activity of Gld2 with
phosphate on S116. We performed nucleotide addition activity
assays with pGld2S116 and with an un-phosphorylated Gld2 control without PKA addition.
PKA-dependent phosphorylation of Gld2 decreased
nucleotide addition activity by two orders of magnitude
(Figure 5d, S4). Significant reductions in activity were
observed for both 15A RNA (~45 fold) and miR-122 (~400
fold) substrates. Although both pGld2S116 and the S116E
phosphomimetic variant reduced nucleotide addition activity,
as we anticipated, the phosphate at S116 had a significantly
stronger inhibitory effect compared to acidic amino acid substitutions (~3 fold). This observation is even more striking in
light of the fact that our pGld2S116 preparations are only
partially phosphorylated (Figure 5c), suggesting phosphorylation of the Gld2 N-terminal domain is a potent mechanism
for the cell to control nucleotide addition activity.
Nucleotide addition activity assays and binding assays were
also performed for the S116A mutant (Table 1, Figure S5).
Alanine substitutions are often used as phospho-ablated
enzyme models. Although the mutant was expected to act
similarly to the wild type enzyme, the alanine substitution in
fact reduced the activity by 23-fold with miR-122. As
described above, the S116E mutation reduced activity by 111fold with miR-122, indicating that a serine residue is crucial at
this position and cannot be replaced by alanine. Thus, S116A
is not an appropriate model for an un-phosphorylated Gld2
and indicates that a serine in position S116 is required for full
activity. We previously showed that alanine is not necessarily
a good model for a non-phosphorylatable residue [36].
Overall, these data indicate that ppAkt1T308,S473 dependent
phosphorylation of Gld2 inactivates Gld2. Our data reveals
a novel molecular pathway linking Akt1 activity to miR-122
stability and activity in vivo.

Discussion
Gld2 activity is regulated by phosphorylation
Gld2 is a key regulator of the stabilization and maturation of
tumour suppressors miR-122 and let-7 [4,7,11]. Cellular
mechanisms that regulate Gld2 mediated nucleotide addition
were previously unknown. Data from HCC cells [18] and
proteomic analysis [29,31] implicated post-translational modification as a potential mechanism regulating Gld2 activity.
Here, we presented the first evidence that serine phosphorylation of Gld2 has a profound impact on catalytic activity and
RNA binding.
We identified phosphorylation sites in the N-terminal
domain of Gld2 that positively or negatively regulate nucleotide addition activity. Our findings are reminiscent of regulation identified in other polymerases. Phosphorylation of
specific serine residues in the C-terminal domain of RNA
polymerase II and in the terminal uridylyltransferase Tut1
regulates their activity and substrate recognition [27,28]. For
RNA polymerase II, serine phosphorylation in the disordered
C-terminal domain is required for promoter clearance [27].
Phosphorylation of the uridylyltransferase Tut1 at position S6

plays a role in its regulation of specific mRNAs and in its
nuclear retention, possibly by facilitating interactions between
Tut1 and nuclear proteins [28]. Similarly, we found that both
phosphomimetic mutations to acidic residues or true phosphorylation of Gld2 at different sites in the N-terminal
domain substantially altered substrate specificity, enhanced,
or abolished enzyme activity. Although these phosphorylation
sites are conserved among mammalian Gld2 proteins, they are
not conserved in the human terminal uridylyltransferases
Tut4 and Tut7, as these enzymes lack the large disordered
N-terminal region.
Undoubtedly, human cells possess a robust Gld2 phosphorylation activity (Figure 3). We found that lysates from EGFstimulated HEK 293 cells were active in phosphorylating Gld2 at
S62. In this particular experiment, we were not able to identify
additional phosphorylation sites in Gld2, suggesting that additional Gld2 kinases may not be activated or sufficiently active in
our experimental conditions. While Akt1 and PKA are expressed
in HEK 293 cells, Akt1 activity in these cells even upon EGF
stimulation is low [37] and likely not sufficient to yield quantitative
phosphorylation of Gld2 S116 required for mass spectrometry.
Alternatively, Gld2 phosphatases may be active at sites other than
Ser62. The data, nevertheless, show that human cells are competent in phosphorylation of Gld2 in its N-terminal domain.
Our experiments with phosphomimetic mutants indicate that
phosphorylation at S62 significantly increases Gld2 activity with
miR-122 and the 15A RNA. Although Gld2 S62E showed
a significant increase in activity with both RNAs, increased
binding affinity was only observed with miR-122. It is interesting
to note that wild-type Gld2 is ninefold more active with miR-122
than with the poly(A) tail mimic. Even the increase in activity
with the poly(A) tail mimic by S62E does not reach the level of
wild type activity with miR-122. In contrast, experiments with
Gld2 S116E and pGld2S116 show that phosphorylation at this site
almost abolishes nucleotide addition activity. Although enzyme
activity is more than 100-fold reduced with miR-122, Gld2
S116E and pGld2S116 still retained very low levels of enzymatic
activity. In comparison, a mutation in the active site, D215A,
completely abolished enzyme activity on miRNA substrates
[4,18]. D215A is part of the conserved catalytic triad responsible
for activity [3,38,39], while S116 is found in the disordered
N-terminal domain, which was previously shown to be dispensable for catalytic activity in the related uridylyltransferase Cid1
[40–42], but we here show that its function lies in the regulation
of enzyme activity. Using enzymatic assays and mass spectrometry, we identified and validated Akt1 and PKA as kinases with
site-specific phosphorylation activity at S116 in Gld2. Although
acidic amino acids are not always able to mimic the functional
impact of phosphate [36], the glutamate variant showed reduced
activity similarly to the pGld2S116 enzyme. Phosphorylation at
S116, however, led to a significantly greater reduction in Gld2
activity, which was two orders of magnitude below the activity of
the un-phosphorylated enzyme. Thus, phosphorylation at S116
effectively controls Gld2 activity.
During HCV infection, the Hepatitis C core protein binds to
Gld2 to inhibit its adenylation activity. Core protein binding is
somewhat inefficient, with 13% binding at a 1:1 ratio.
Nonetheless, this inhibition leads to a reduction of cellular
miR-122 levels by 30%[18]. Even partial phosphorylation of
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cellular Gld2 at S116 is expected to have a similar or greater
effect on miR-122 levels, making posttranslational modification
of Gld2 an efficient means to control cellular miRNA levels.
Although phosphorylation of S116 inhibits Gld2 catalytic
activity, RNA binding affinity was unperturbed, suggesting
Gld2 phosphorylated at S116 binds the RNA substrate in
a non-productive conformation. The crystal structures of
related nucleotidyltransferases from yeast [43] and
C. elegans [15,44] as well as the human terminal uridylyltransferases Tut1 and Tut7 [45,46] revealed a conserved
positively charged surface that may facilitate RNA binding.
Despite these efforts, no structural information is available
on the N-terminal domain of Gld2. Our data suggest that
Gld2 can assume different RNA binding modes. The wildtype Gld2 enzyme binds RNA with high affinity in
a catalytically competent mode, which is perhaps stabilized
yet further in the activating mutants S62E and S110E.
Conversely, Gld2 variants with phosphomimetic substitution or phosphorylation at S116 appear to bind the RNA
substrate in a non-catalytic mode that interferes with
nucleotide addition. This is not unique to Gld2, as other
cases of catalytically incompetent enzymes have been
described in the literature. A small deletion in RNA polymerase (RNAP) leads to a catalytically incompetent RNAP
that remains bound to the promoter complex [47]. It is also
well known that phosphorylation of the C-terminal domain
of RNAP II is required for promoter clearance but not its
activity [27,48]. While the structural basis for phosphorylation-dependent modulation of Gld2 activity is not yet
defined, our experiments suggest an allosteric mechanism.
We identified Gld2 variants that impact activity independently of RNA binding, indicating that allosteric or conformational changes in the Gld2 RNA complex may play an
important role in Gld2 catalysed nucleotide addition.
Furthermore, in the cell, phosphorylation of Gld2 may
affect interactions with proteins that are implicated in RNA
substrate selectivity [12,49–52]. In humans, Gld2 was recently
shown to interact with the RNA-binding protein Quaking
(QKI-7) to facilitate polyadenylation of target mRNAs. QKI7 was shown to bind between residues 1–141 on Gld2 [52],
which correspond to the disordered N-terminal domain,
including all of the phosphorylation sites investigated here.
Future efforts will determine the effect of phosphorylation on
the ability of RNA binding proteins to interact with and
regulate Gld2 activity and substrate specificity.
Oncogenic protein kinases signal to miRNA regulation
We identified Gld2 as a previously unknown substrate of two
oncogenic kinases. PKA and Akt1 belong to the evolutionarily
conserved AGC family of protein kinases that are activated
upon stimulation with growth factors such as EGF [53]. PKA
is the key kinase in the cyclic AMP signalling pathway that is
activated upon hormone binding to G-protein coupled receptors (GPCR). PKA activation has been shown to modulate the
expression of miR-122 through the extracellular signalregulated kinase (ERK) [54] and miRNA let-7b levels through
protein phosphatase 2A (PP2A) activation but the underlying
pathway remained unclear [55].
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Akt1 is a central hub of the PI3K/Akt signalling pathway,
which is the most commonly activated signal transduction
pathway in human cancers [56]. Active Akt1 signals for cell
survival and proliferation while also inhibiting apoptosis [53].
Akt1 activity is dependent on phosphorylation at two key
regulatory sites (T308, S473). Over-active and hyperphosphorylated Akt1 is a hallmark of diverse human malignancies [56,57], while the unmodified Akt1 protein is inactive
and rapidly degraded in cells [58]. Several reports show that
Akt1 expression is regulated by miRNAs. The miRNAs miR564 and miR-215 directly negatively regulate Akt1 mRNA
stability [59,60], while miRNA let-7 inhibits cyclin D1 expression, leading to reduced Akt1 phosphorylation at S473 [61].
Conversely, miRNA-122 overexpression is associated with
increased Akt1 phosphorylation in T-cell lymphoma and
renal cell carcinoma cells [62], enhancing cancer progression.
These reports correlate PKA or Akt1 activity with miRNA
levels yet fail to identify the factor linking PKA or Akt1
activity to miRNA levels, exposing gaps in our understanding
of the signal transduction network. In addition, neither PKA
nor Akt1 were previously shown to directly phosphorylate any
regulator of RNA.
Although miRNAs are known to regulate Akt1, the ability
of Akt1 activity to control an enzyme involved in the regulation of miRNA metabolism has not been documented previously. The Akt isozyme Akt2 is known to phosphorylate the
single-stranded RNA binding protein KH-type splicing regulatory protein (KSRP), allowing it to switch its RNA preference from mRNA to primary miRNA (pri-miRNA) and
facilitate Drosha processing to pre-miRNA [63]. Although
KSRP binds RNA, no enzyme that directly regulates RNA
stability has been previously identified as a substrate of
Akt1. Using precise biochemical experiments, we found that
both Akt1 and PKA site-specifically phosphorylate Gld2 at
S116, near abolishing Gld2 activity with miRNA and mRNA
substrates.
Relevance of Gld2 phosphorylation to disease
Hyperactivity of Akt1 and PKA is common in many cancers
[64,65]. Our data suggest that phosphorylation of Gld2 by
these kinases would further promote carcinogenesis by destabilizing tumor suppressor miRNAs, thus, further inducing
tumorigenesis. Abolishing Gld2 activity leads to a decrease
in levels of tumor suppressor miRNAs including miR-122 and
let-7 [7,16] (Figure 6). Decreased miR-122 and let-7 levels and
activity enable over- or un-regulated expression of their target
genes, including oncogenes with roles in cell growth, metastasis, and apoptosis [16,66].
In a related disease context, Gld2 is downregulated in
Hepatitis B and inhibited in Hepatitis C infections [16,18].
Both HBV and HCV are contributing factors in the development of HCC and other liver diseases due to the dysregulation
in miR-122 levels and the resulting expression of miR-122
regulated oncogenes [16,19]. The extent of Gld2 catalysed
mRNA adenylation, and the effect of specific phosphorylations on the transcriptome and miRnome remain to be investigated and may reveal additional contributions of Gld2
regulation to pathogenesis.
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Figure 6. Model of Akt1-mediated regulation of Gld2. Gld2 monoadenylates miRNAs to increase stability and adds a single nucleotide to pre-miRNAs to enable
recognition by Dicer and miRNA maturation. Decreased miRNA levels (e.g. let-7b [55]) are associated with decreased Akt1 phosphorylation status and activity.
Conversely, fully activated Akt1 (ppAkt1T308,S473) phosphorylates Gld2 at S116 and silences the stabilizing/maturing effect of Gld2 on miRNA. Thus, through
phosphorylation of Gld2, Akt1 activity is expected to reduce miRNA levels. Phosphorylation is indicated by the orange circles.

Conclusion
While hundreds of Akt1 substrates have been validated and/or
predicted in human cells [67], miRNA editing enzymes were
not previously known to be part of the Akt1 signalling network.
Similarly, it was unclear how Gld2 activity may be regulated to
respond to external stimuli and signaling pathways, in turn
controlling miRNAs and an even larger number of downstream
mRNA substrates. We here revealed the first link between the
activity of oncogenic kinases Akt1 and PKA and the regulation
of Gld2. We found that HEK 293 cells contain N-terminal Gld2
kinase activity and that phosphorylation sites in the N-terminal
domain of Gld2 can either positively or negatively regulate
nucleotide addition activity. We identified Gld2 as a bona fide
substrate of PKA and Akt1, and the site-specific phosphorylation catalysed by either kinase at Gld2 S116 abolishes nucleotide
addition activity. While the overall impact of Akt1/PKA signalling on miRNA metabolism remains to be investigated in
a cellular context, these data significantly enhance our knowledge on miRNA regulation and reveal a previously unrecognized link between oncogenic signal transduction and the
regulation of tumor suppressor miRNAs.

Materials and methods
Multiple sequence alignment
Alignments were performed as previously described [14]. Briefly,
250 mammalian Gld2 sequences were downloaded from NCBI.
Sequence alignment and alignment editing were performed with
Muscle [68], MultiSeq from VMD 1.8.7 [69], and Wasabi [70].
Plasmids, protein purification, and western blotting
Homo sapiens Gld2 was codon-optimized (Genewiz, South
Plainfield, NJ, USA) for expression in Escherichia coli. The
gene was cloned into pGEX-6P-2 with a N-terminal TEV cleavage site using BamHI and XhoI restriction sites. Mutants were

generated through site-directed mutagenesis [33]. All primers
are listed in Table S1. Successful cloning was verified by DNA
sequencing at the London Regional Genomics Centre, London,
ON, Canada. Gld2 protein production, purification, and
Western blotting details are in the Supplementary Data.
Cloning of Akt1 and PDK1 and Akt1 production and purification were previously described [36].

Nucleotide addition assay
Gld2-catalysed reactions and product quantification were carried out as described previously [14]. Specific details can be
found in the Supplementary Data.

Fluorescence anisotropy
Various concentrations of Gld2 were incubated with 20 nM 5ʹend labelled miR-122 (22 nt) or 15A RNA (15 nt) room temperature in the dark. The RNAs were labelled on the 5ʹ-end with
6-carboxyfluorescein (6-FAM) (Sigma-Aldrich). Fluorescence
polarization was measured on a Victor3V (PerkinElmer) with an
excitation of 492 nm and emission of 535/20 nm and a binding
curve was generated to calculate the dissociation constants (KD).
More details can be found in the Supplementary Data.

Identification of potential kinases
Two online tools were used to generate a list of potential Gld2
kinases. PhosphoMotif Finder identifies putative kinase binding sequences in a query sequence based on the binding
motifs of kinases as well as their substrate sequences identified
in the literature [34]. GPS 3.0 predicts kinase phosphorylation
sites in the query sequence using a computational prediction
program [35].

RNA BIOLOGY

1031

Dot plot kinase activity assays

Mass spectrometry

Kinase assays were performed as previously described [36].
Briefly, reactions containing a kinase, wild-type Gld2, and
[γ-32P]-ATP (Perkin Elmer) were carried out at 37°C Samples
were taken at various timepoints and stopped by spotting on P81
paper. The P81 paper was washed, air-dried, exposed to
a phosphor screen, and visualized with a phosphorimager
(Storm 860 Molecular Imager).

Mass spectrometry (MS) analysis of tryptic digested peptides
was carried out on the EasyLC1000-QExactive tandem LC-MS
system (ThermoFisher Scientific). A full scanning (full MS/
dd-MS2 TopN, data-dependent acquisition mode in
a Q-Exactive) was performed to obtain an overview of all
possible protein modifications within Gld2. Parallel-reaction
monitoring (PRM) was then carried out to further verify the
phosphorylation at S62 or S116 in Gld2. We analysed Gld2
and Gld2 phosphorylated by purified recombinant kinases
and by HEK 293 cell extract. Gld2 or pGld2 were precipitated
in ice-cold acetone/ethanol/acetic acid (50/50/0.1 v/v/v). The
protein precipitate was re-suspended in 8 M urea then
reduced in 5 mM DTT at 37°C for 1 hr and alkylated in
14 mM iodoacetamide (IAA) in darkness at RT for 1 hr.
Unreacted IAA was neutralized by adding 5 mM DTT and
final protein concentration was determined by Bradford assay.
Trypsin digestion was performed at 37°C overnight with
a protein: trypsin ratio of 20:1 w/w. The digest was desalted
in a C18 column (Phenomenex, Torrance, CA, USA) according to the manufacturer’s protocol and re-suspended in MSgrade water for MS injection. Data were analysed using
Skyline software [73].

Kinase activity assays using SDS gels
In the following assays, Gld2 was tested as a protein substrate for
several human kinases. Kinase assays were performed in 60 µL
reactions containing 900 nM Gld2, kinase buffer (20 mM MOPS
[pH 7.0], 25 mM β-glyceraldehydephosphate, 25 mM MgCl2,
5 mM EGTA [pH 8.0], 1 mM Na2VO4, 0.1 mM ATP, 13.2 nM
[γ-32P]-ATP (Perkin Elmer)). Reactions were initiated with the
addition of the specified kinase. Since kinases varied in activity,
final concentrations were adjusted according to published values
using 25 nM CK2α, 1.43 nM CK2 holoenzyme, 33 nM fully
activated ppAkt1T308,S473, 30 nM Abl, 0.45 nM PKA, or 12 nM
CDK5 in a kinase dilution buffer (0.1 mg/mL BSA, 5 mM MOPS
[pH 7.2], 25 mM β-glyceraldehydephosphate, 5 mM MgCl2,
1 mM EGTA [pH 8.0], 1 mM Na2VO4, 100 mM NaCl).
Reactions were incubated at 37°C for 15 min on
a microcentrifuge shaker. Samples (20 µL) were taken every 5
min and the reaction was stopped with the addition of 2 x SDS
loading dye. Purified recombinant kinases CK2α, CK2 holoenzyme, Abl, PKA, and CDK5 were a generous gift from Dr David
W. Litchfield (The University of Western Ontario, Canada).
Reaction products at each time point were separated on a 10%
polyacrylamide SDS gel. The gel was exposed to a storage phosphor screen overnight at −80°C and visualized with
a phosphorimager (Storm 860 Molecular Imager). Kinase assays
and quantification were previously described [36,71]. Kinase
assays using unlabelled ATP for further downstream assays are
described in the Supplementary Data.

Phosphorylation of Gld2 using HEK 293 cell extract
HEK 293 cells in 100 mm plates were grown to approximately
90% confluency in Dulbecco’s Modified Eagle’s Medium
(DMEM) (319–005-3L, Wisent) with 10% fetal bovine serum
(FBS) (098150, Lot 185,700, Wisent) and 1% penicillinstreptomycin (450–201-EL, Wisent) as described previously
[72]. Epidermal growth factor (EGF) was added to each plate
to a final concentration of 50 ng/mL and incubated at 37°C
for 1 hr. Cells were harvested and resuspended in 5 x kinase
buffer with 5 mM phenylmethylsulfonyl fluoride (PMSF).
Cells were broken with a Q125 Sonicator (Qsonica) six
times at 20% amplitude and 1 sec on, 1 sec off. Using the
cell extract as a source of active kinases, we performed
a kinase reaction. This was repeated with unstimulated HEK
293 cell extract. Gld2 was isolated using a GST Spintrap
column, and possible Gld2 phosphorylation sites were analysed by mass spectrometry.
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